Table 1 Results of evaluation

RX-SX

RX-DX

DX-SX

1

Metolazone-Shortness of Breath

0.086(0.075–0.097)

Metolazone-Hypertensive Disease 0.526(0.495–0.557)

Hypertensive Disease-Shortness of Breath 0.132(0.113–0.152)

I

I

2

Metolazone-Headache

0.070(0.059–0.083)

Metolazone-Hypertensive Disease

0.526(0.495–0.557)

Hypertensive Disease-Headache

0.084(0.072–0.095)

E

E

3

Metolazone-constipation

0.034 (0.023–0.046)

Metolazone-Hypertensive Disease

0.526(0.495–0.557)

Hypertensive Disease-constipation 0.019(0.009–0.028)

E

D

4

Rosiglitazone-Headache

0.079 (0.068–0.091)

Rosiglitazone-Diabetes

0.443(0.327–0.513)

Diabetes-Headache

0.117(0.093–0.128)

I

D

5

Rosiglitazone-Chest Pain

0.077(0.069–0.088)

Rosiglitazone-Diabetes

0.443(0.327–0.513)

Diabetes-Chest Pain

0.090(0.074–0.115)

E

E

DX ₁ - SX

DX ₁ - DX ₂

DX ₂ - SX

6

Hypertensive Disease-Shortness of Breath 0.132(0.113–0.152)

Hypertensive Disease-Heart Failure 0.651(0.563–0.738)

Heart Failure-Shortness of Breath

0.173(0.158–0.186)

I

I

7

Diabetes-Chest Pain

0.131(0.115–0.148)

Diabetes-Heart Failure

0.435(0.317–0.543)

Heart Failure-Chest Pain

0.184(0.169–0.193)

I

I